DE60032524D1 - EP4 Rezeptor Ligand und Verwendung gegen neuropatischen Schmerzen, Colon Krebs, HIV und Migräne - Google Patents

EP4 Rezeptor Ligand und Verwendung gegen neuropatischen Schmerzen, Colon Krebs, HIV und Migräne

Info

Publication number
DE60032524D1
DE60032524D1 DE60032524T DE60032524T DE60032524D1 DE 60032524 D1 DE60032524 D1 DE 60032524D1 DE 60032524 T DE60032524 T DE 60032524T DE 60032524 T DE60032524 T DE 60032524T DE 60032524 D1 DE60032524 D1 DE 60032524D1
Authority
DE
Germany
Prior art keywords
migraine
hiv
colon cancer
neuropathic pain
receptor ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60032524T
Other languages
English (en)
Other versions
DE60032524T2 (de
Inventor
Mark Bamford
Richard Howard Green
Richard Coles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9918745.2A external-priority patent/GB9918745D0/en
Priority claimed from GBGB9928437.4A external-priority patent/GB9928437D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DE60032524D1 publication Critical patent/DE60032524D1/de
Publication of DE60032524T2 publication Critical patent/DE60032524T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60032524T 1999-08-10 2000-08-08 EP4 Rezeptor Ligand und Verwendung gegen neuropathischen Schmerzen, Colon Krebs, HIV und Migräne Expired - Lifetime DE60032524T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9918745 1999-08-10
GBGB9918745.2A GB9918745D0 (en) 1999-08-10 1999-08-10 Medical uses
GBGB9928437.4A GB9928437D0 (en) 1999-12-01 1999-12-01 Medical uses
GB9928437 1999-12-01

Publications (2)

Publication Number Publication Date
DE60032524D1 true DE60032524D1 (de) 2007-02-01
DE60032524T2 DE60032524T2 (de) 2007-07-05

Family

ID=26315833

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60012751T Expired - Lifetime DE60012751T2 (de) 1999-08-10 2000-08-08 Verwendung von EP 4 Rezeptorliganden zur Behandlung von neuropathischem Schmerz
DE60032524T Expired - Lifetime DE60032524T2 (de) 1999-08-10 2000-08-08 EP4 Rezeptor Ligand und Verwendung gegen neuropathischen Schmerzen, Colon Krebs, HIV und Migräne

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60012751T Expired - Lifetime DE60012751T2 (de) 1999-08-10 2000-08-08 Verwendung von EP 4 Rezeptorliganden zur Behandlung von neuropathischem Schmerz

Country Status (8)

Country Link
US (1) US6861441B1 (de)
EP (2) EP1442744B1 (de)
JP (1) JP2003506404A (de)
AT (2) ATE348608T1 (de)
AU (1) AU6836200A (de)
DE (2) DE60012751T2 (de)
ES (2) ES2225199T3 (de)
WO (1) WO2001010426A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720270D0 (en) 1997-09-25 1997-11-26 Pharmagene Lab Limited Medicaments for the treatment of migraine
ATE395058T1 (de) * 2000-03-24 2008-05-15 Asterand Uk Ltd Verwendung von prostanoid-ep4-rezeptor- antagonisten zur behandlung von kopfschmerzen und nachweisverfahren für solche antagonisten
GB0030541D0 (en) * 2000-12-14 2001-01-31 Glaxo Group Ltd Medical uses
GB0031295D0 (en) * 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0103269D0 (en) * 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
US20050059742A1 (en) * 2001-10-31 2005-03-17 Jabbour Henry Nicolas Antagonists of prostaglandin receptors ep2 and/or ep4 for the treatment of dysmenorrhea and menorphagia
WO2004032965A1 (ja) 2002-10-10 2004-04-22 Ono Pharmaceutical Co., Ltd. 内因性修復因子産生促進剤
GB0302094D0 (en) * 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
CA2563356A1 (en) * 2004-04-20 2005-11-03 Pfizer Products Inc. Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists
UY30121A1 (es) * 2006-02-03 2007-08-31 Glaxo Group Ltd Nuevos compuestos
GB0602900D0 (en) * 2006-02-13 2006-03-22 Glaxo Group Ltd Novel Compounds
GB0615111D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel compounds
GB0616498D0 (en) * 2006-08-18 2006-09-27 Glaxo Group Ltd Novel compounds
GB0620619D0 (en) * 2006-10-17 2006-11-29 Glaxo Group Ltd Novel compounds
GB0623203D0 (en) * 2006-11-21 2007-01-03 Glaxo Group Ltd Novel compounds
MX2009012043A (es) * 2007-05-08 2010-02-18 Nat Univ Corp Hamamatsu Activador de celulas t citotoxicas que comprende agonista ep4.
GB0715463D0 (en) * 2007-08-08 2007-09-19 Glaxo Group Ltd Novel compounds
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
ES2960438T3 (es) * 2009-04-22 2024-03-04 Askat Inc Sustancia antagonista del receptor EP4 selectivo para el tratamiento del cáncer
WO2011068993A1 (en) * 2009-12-02 2011-06-09 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life of fc fusion proteins.
US8883982B2 (en) 2011-06-08 2014-11-11 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
WO2013090552A1 (en) * 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
JP2015522528A (ja) 2012-05-09 2015-08-06 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 慢性閉塞性肺疾患の予防または治療方法および医薬組成物
JP6400479B2 (ja) 2012-10-29 2018-10-03 株式会社カルディオ 肺疾患特異的治療剤
US9968716B2 (en) 2013-10-15 2018-05-15 Ono Pharmaceutical Co., Ltd. Drug-eluting stent graft
ES2907285T3 (es) * 2014-03-06 2022-04-22 Elanco Animal Health Incorporated Composiciones de grapiprant y procedimientos de uso de las mismas
CN109952314A (zh) 2016-09-23 2019-06-28 泰瓦制药国际有限公司 治疗难治性偏头痛
US10342785B2 (en) 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH574409A5 (en) * 1972-09-29 1976-04-15 Sandoz Ag Benzo(f)isoindoline derivs - with antidepressant and analgesic activity
JPS5718671A (en) * 1980-04-30 1982-01-30 Glaxo Group Ltd Aminocyclopentane alkenoic acid and esters thereof,manufacture and drug composition
US4618683A (en) * 1982-06-01 1986-10-21 Abbott Laboratories Tetrahydro-6,7-dimethoxy-1H-benz[e]isoinodolines useful in the treatment of hypertension and as sedatives
NO872963L (no) * 1986-07-29 1988-02-01 Glaxo Group Ltd Isokinolinderivater.
EP0501579A1 (de) * 1991-02-28 1992-09-02 Merck Frosst Canada Inc. Naphthalinlactone als Inhibitoren der Leukotrien-Biosynthese
EP0520573A1 (de) 1991-06-27 1992-12-30 Glaxo Inc. Derivate von cyclischen Imiden
WO1995029900A1 (en) * 1994-04-29 1995-11-09 Takeda Chemical Industries, Ltd. CONDENSED HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE AS GnRH ANTAGONISTS
JPH10510540A (ja) * 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
AUPO713297A0 (en) * 1997-06-02 1997-06-26 Fujisawa Pharmaceutical Co., Ltd. Oxazole compound
GB2330307A (en) 1998-02-07 1999-04-21 Glaxo Group Ltd EP4 Receptor antagonists as bone resorption inhibitors

Also Published As

Publication number Publication date
JP2003506404A (ja) 2003-02-18
ES2225199T3 (es) 2005-03-16
WO2001010426A3 (en) 2001-12-20
EP1442744A3 (de) 2005-04-06
US6861441B1 (en) 2005-03-01
EP1442744B1 (de) 2006-12-20
DE60012751D1 (de) 2004-09-09
ATE272398T1 (de) 2004-08-15
WO2001010426A2 (en) 2001-02-15
EP1202730B1 (de) 2004-08-04
EP1442744A2 (de) 2004-08-04
ATE348608T1 (de) 2007-01-15
DE60012751T2 (de) 2005-01-20
AU6836200A (en) 2001-03-05
DE60032524T2 (de) 2007-07-05
ES2274378T3 (es) 2007-05-16
EP1202730A2 (de) 2002-05-08

Similar Documents

Publication Publication Date Title
DE60032524D1 (de) EP4 Rezeptor Ligand und Verwendung gegen neuropatischen Schmerzen, Colon Krebs, HIV und Migräne
ATE260255T1 (de) 5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate
ZA200309887B (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
MXPA04004674A (es) Ligados de los receptors de los canabinodies.
CY1109989T1 (el) 3,4-di-υποκαθισταμενες cyclobutene-1,2-diones ως συνδετες του υποδοχεα των cxc-χημειοκινων
DE60330757D1 (de) Verwendung von pyridylamiden als angiogenesehemmer
FI924397A (fi) Substituerade pyrimidiner
DE60003863D1 (de) Dioxocyclopentylhydroxamsäure
GB0031103D0 (en) Chemical compounds
ATE278661T1 (de) Anthranilsäurederivate
ATE498600T1 (de) Inden derivate als pharmazeutika
BR0105563A (pt) Derivados e análogos de galantamina
DE60015390D1 (de) Antidiabetische thiazolidindione und ihre herstellung
DE69810960D1 (de) 2-phenoxyanilin-derivate
DK1209151T3 (da) 4-substituerede piperidinderivativer
DE60043497D1 (de) 4-Substituierte-3,6-Anhydro-Galaktosederivate und ihre pharmazeutische Verwendung
IL157440A0 (en) Triazole derivatives and pharmaceutical compositions containing the same
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
DE60020246D1 (de) Substituierte benzylthiazolidin-2,4-dion derivate
ATE252546T1 (de) 3-(3-hydroxyphenyl)-3-amino-propionamidderivate
ATE334977T1 (de) Discodermolid-analoga und ihre pharmazeutische verwendung
ATE319452T1 (de) Arzneimittel gegen essstörungen
EP1466900A4 (de) 2-substituierte vitamin-d-derivate
ATE296293T1 (de) Substituierte benzylthiazolidin-2,4-dion derivate
CY1110529T1 (el) Παρασκευη ν-υποκατεστημενων 2,7-διαλκυλο-4-υδροξυ-5-αμινο-8-αρυλοοκτανοϋλαμιδιων

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: BAMFORD, MARK, HARLOW ESSEX, CM19 5AW, GB

Inventor name: GREEN, RICHARD HOWARD, DECEASED, GB

Inventor name: COLES, RICHARD, STEVENAGE HERTFORDSHIRE, SG1 2, GB

8364 No opposition during term of opposition